Literature DB >> 29987589

Low specificity of voltage-gated calcium channel antibodies in Lambert-Eaton myasthenic syndrome: a call for caution.

Rodica Di Lorenzo1, Karin Mente2,3, Jianbo Li4, Luay Shayya5, Alexander Rae-Grant1, Yuebing Li1, Adham Jammoul6.   

Abstract

As testing for neuronal antibodies become more readily available, the spectrum of conditions potentially associated with these autoantibodies has been widening. Voltage-gated calcium channel antibodies (VGCC-Ab) are no exception to this trend. The significance of an elevated VGCC-Ab titer beyond its original clinicopathological correlate, Lambert-Eaton myasthenic syndrome (LEMS) remains undetermined. We sought to determine the diagnostic significance of an elevated serum VGCC-Ab titer in a large single-center cohort of 100 patients. The majority of patients (58%) with elevated VGCC-Ab levels lacked an inflammatory or autoimmune etiology of their neurologic diagnosis. Only six cases (6%) of LEMS and two cases (2%) of SCLC (without LEMS) were identified. No significant differences in antibody titers were seen between the autoimmune and non-autoimmune groups. These findings support the notions that: (a) elevated VGCC-Ab titers without clinical correlation must be interpreted with caution, and (b) the clinical and electrodiagnostic criteria for LEMS should remain the mainstay in the diagnosis of LEMS.

Entities:  

Keywords:  Autoimmune encephalitis; Lambert–Eaton myasthenic syndrome; Neurological paraneoplastic syndrome; Voltage-gated calcium channel antibody

Mesh:

Substances:

Year:  2018        PMID: 29987589     DOI: 10.1007/s00415-018-8959-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  20 in total

1.  P/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments.

Authors:  Nicholas L Zalewski; Vanda A Lennon; Daniel H Lachance; Christopher J Klein; Sean J Pittock; Andrew Mckeon
Journal:  Muscle Nerve       Date:  2016-02-08       Impact factor: 3.217

2.  A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.

Authors:  D B Sanders; J M Massey; L L Sanders; L J Edwards
Journal:  Neurology       Date:  2000-02-08       Impact factor: 9.910

3.  Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.

Authors:  Shin J Oh; Natalya Shcherbakova; Anna Kostera-Pruszczyk; Mohammad Alsharabati; Mazen Dimachkie; Jose Munoz Blanco; Thomas Brannagan; Dragana Lavrnić; Perry B Shieh; Christophe Vial; Andreas Meisel; Samuel Komoly; Benedikt Schoser; Kumaraswamy Sivakumar; Yuen So
Journal:  Muscle Nerve       Date:  2016-03-03       Impact factor: 3.217

4.  Clinical experience of seropositive ganglionic acetylcholine receptor antibody in a tertiary neurology referral center.

Authors:  Yuebing Li; Adham Jammoul; Karin Mente; Jianbo Li; Robert W Shields; Steven Vernino; Alexander Rae-Grant
Journal:  Muscle Nerve       Date:  2015-06-30       Impact factor: 3.217

5.  Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome.

Authors:  M Motomura; B Lang; I Johnston; J Palace; A Vincent; J Newsom-Davis
Journal:  J Neurol Sci       Date:  1997-03-20       Impact factor: 3.181

6.  Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome.

Authors:  B Lang; J Newsom-Davis; D Wray; A Vincent; N Murray
Journal:  Lancet       Date:  1981-08-01       Impact factor: 79.321

7.  Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.

Authors:  P W Wirtz; J J Verschuuren; J G van Dijk; M L de Kam; R C Schoemaker; J G C van Hasselt; M J Titulaer; U R Tjaden; J den Hartigh; J M A van Gerven
Journal:  Clin Pharmacol Ther       Date:  2009-04-08       Impact factor: 6.875

8.  Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes.

Authors:  V A Lennon; T J Kryzer; G E Griesmann; P E O'Suilleabhain; A J Windebank; A Woppmann; G P Miljanich; E H Lambert
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

9.  Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results.

Authors:  Hesham Abboud; Ian Rossman; Maureen A Mealy; Eddie Hill; Nicolas Thompson; Aditya Banerjee; John Probasco; Michael Levy
Journal:  J Neurol       Date:  2017-10-03       Impact factor: 4.849

10.  3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.

Authors:  Donald B Sanders; Vern C Juel; Yadollah Harati; A Gordon Smith; Amanda C Peltier; Tessa Marburger; Jau-Shin Lou; Robert M Pascuzzi; David P Richman; Tai Xie; Valentin Demmel; Laura R Jacobus; Kathy L Aleš; David P Jacobus
Journal:  Muscle Nerve       Date:  2018-02-02       Impact factor: 3.217

View more
  2 in total

1.  Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome.

Authors:  Elyse E Lower; Madison Sturdivant; Robert P Baughman
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

Review 2.  Autoimmune Neurology: The Need for Comprehensive Care.

Authors:  Justin R Abbatemarco; Stefanie J Rodenbeck; Gregory S Day; Maarten J Titulaer; Anusha K Yeshokumar; Stacey L Clardy
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-06-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.